Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by PWIB123on Jul 25, 2024 12:46pm
196 Views
Post# 36148269

Do we have any anecdotal information?

Do we have any anecdotal information?I stepped away from paying much attention for some time while taking care of my father, who had Stage IV Neuroendocrine Rectal Cancer.  Dad passed away on May 29th, after around a 1 year fight this second time having the same form of rectal cancer.  I'm getting back to my more normal routines, but still playing major catch up.  

Based on the board activity.  It looks like everyone has pretty much lost interest and are simply waiting on oncology results and/or for profit to grow by streamlining the company going forward.  I cannot believe Paul is even contemplating an acquisition at this point, but I'm assuming that's just another selling tactic and attempt at giving investors something to look forward too.  I actually like what the company has been able to accomplish, but I am a little worried about those sales projections.  They've never been honest about anything in the past.  

Does anyone have any anecdotal information on the oncology platform?  That's the only reason why I'm here, and it still feels like a complete lottery ticket at this point.
<< Previous
Bullboard Posts
Next >>